Every 10-Q that ProKidney Corp. (PROK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PROK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PROK filings page.
ProKidney Corp., a late-clinical-stage biotech developing the autologous cell therapy rilparencel for advanced diabetic CKD, reported continued operating losses and a strained liquidity position for the quarter and six months ended June 30, 2026.
For the first half of 2026, revenue from building lease income was $0.4 million, while operating expenses reached $93.7 million, driven mainly by research and development of $69.9 million and general and administrative costs of $23.7 million. Net loss before noncontrolling interest was $89.1 million, compared with $74.9 million a year earlier, and net loss attributable to Class A shareholders was $48.5 million, or $0.29 per share.
Cash and cash equivalents plus marketable securities totaled $181.6 million at June 30, 2026, down from $270.0 million at year-end 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern, as existing liquidity is not expected to fund obligations for 12 months following the August 10, 2026 filing date without additional financing or strategic arrangements. The Phase 3 PROACT 1 study has completed enrollment for patients contributing to the accelerated-approval surrogate endpoint, with topline eGFR slope data expected in the second quarter of 2027.
ProKidney Corp. reported a larger net loss as it advances its lead kidney therapy. For the three months ended March 31, 2026, net loss available to Class A stockholders was $20.0 million, or $0.14 per share, versus $16.7 million or $0.13 a year earlier.
Research and development spending rose to $33.8 million, mainly from higher Phase 3 PROACT 1 trial and manufacturing costs, while general and administrative expenses fell to $11.3 million on lower equity-based compensation and professional fees. Cash used in operating activities was $41.7 million.
As of March 31, 2026, ProKidney held $101.9 million in cash and cash equivalents and $123.0 million in marketable securities, for total assets of $292.8 million. The company expects this liquidity to fund operations into mid-2027 while it runs its Phase 3 study of rilparencel, with key efficacy readouts anticipated in 2027 and 2029.
ProKidney (PROK) reported Q3 2025 results with a net loss including noncontrolling interest of $35.8 million and a net loss available to Class A stockholders of $16.5 million, or $0.12 per share. Revenue was $217,000, reflecting leasing income from tenant agreements.
Operating expenses were $38.8 million, down from $49.0 million a year ago, as research and development totaled $26.8 million and general and administrative was $11.9 million. For the nine months, revenue reached $668,000 and operating loss was $119.6 million.
Liquidity consisted of $95.3 million in cash and cash equivalents and $176.4 million in marketable securities as of September 30, 2025. Net cash used in operating activities was $87.6 million for the nine months. The company sold 1,989,147 Class A shares under its 2025 at-the-market program for $7.1 million during the quarter and, after quarter-end, an additional 5,463,195 shares for $17.1 million in proceeds.
ProKidney completed a domestication to Delaware and related restructuring effective July 1, 2025; management states these transactions did not have a significant impact on the financial statements.
ProKidney Corp. reported a substantial operating loss as it advances its lead autologous cell therapy, rilparencel, through late-stage trials while funding clinical and manufacturing operations. For the six months ended June 30, 2025 the consolidated net loss before noncontrolling interest was $74.9 million, cash and cash equivalents were $84.9 million and marketable securities totaled $209.8 million, giving combined short-term liquidity of about $294.7 million. Total assets were $372.1 million and stockholders' deficit was $1.0025 billion, reflecting a large redeemable noncontrolling interest of $1.342 billion.
The company is progressing Phase 3 PROACT 1 to support accelerated approval of rilparencel: the FDA agreed that eGFR slope can serve as a surrogate endpoint for an accelerated BLA and specified an acceptable effect size of at least 1.5 mL/min/1.73m2/year. ProKidney completed the REGEN-007 Phase 2 trial showing in one dosing arm a statistically significant improvement in annual eGFR slope of 4.6 mL/min/1.73m2/year (p<0.001). The company has enrolled nearly half the patients required for the accelerated approval analysis, with topline eGFR slope readout anticipated in Q2 2027.